Rep. Michael A. Rulli (R-OH) sits on the House Health, Employment, Labor, and Pensions subcommittee, which oversees drug pricing and pharmaceutical supply chains. He also traded LLY, Eli Lilly and Company, the maker of Mounjaro and Zepbound, three times between December 2025 and July 2026. The slowest of those trades arrived 248 days after execution. The STOCK Act gives members 45 days.
The three trades, all in the $1,000 to $15,000 range, were reported in a single filing. Rulli sold LLY on Dec 2, 2025, bought it on Jan 2, 2026, and sold again on Jul 1, 2026. The dollar value of the combined transactions is roughly $24,000, based on the reported ranges.
| Date | Type | Amount | Owner |
|---|---|---|---|
| Dec 2, 2025 | Sell | $1K-$15K | Self |
| Jan 2, 2026 | Buy | $1K-$15K | Self |
| Jul 1, 2026 | Sell | $1K-$15K | Self |
The 248-day lag applies to the July 1, 2026 sale. The Dec 2 and Jan 2 trades also came in late, but the filing does not specify their exact report dates. A 248-day delay is more than five times the legal limit. The STOCK Act, passed in 2012, requires members to disclose most stock trades within 45 days of execution. Late filings carry a $200 penalty for each missed deadline, though the Ethics Committee can waive it.
Rulli is a first-term Republican from Ohio's 6th District. He has made 32 career trades since taking office. Eli Lilly is one of the most actively traded stocks among lawmakers: 66 members have reported positions in the company. The stock trades on the NYSE with a market cap of $929.3 billion. Its 52-week range runs from $625.90 to $1,249.45, and the current price is $1,225.83.
The committee overlap is direct. Rulli's subcommittee, Health, Employment, Labor, and Pensions, falls under the House Committee on Education and Workforce. It has jurisdiction over employer-sponsored health plans, which are major purchasers of Lilly's GLP-1 drugs. The House Energy and Commerce Committee, where Rulli also sits, oversees the FDA and drug approval processes. Lilly's blockbuster products, Mounjaro and Zepbound, have driven the company's recent growth and drawn scrutiny over list prices and insurance coverage.
The filing does not state a reason for the trades. A disclosure is a record of a transaction, not evidence of wrongdoing. But the timing and the panel overlap are now part of the public record. Rulli's office did not respond to a request for comment.
For comparison, the latest congressional trades database shows most members file within the 45-day window. Rulli's 248-day lag is among the longest in the current cycle.